Researchers sought to determine whether fixed-duration treatment with venetoclax + obinutuzumab/ibrutinib would have similar efficacy to continuous ibrutinib therapy in CLL.
Jaypirca showed higher overall response rates than Imbruvica in both treatment-naive and relapsed/refractory CLL/SLL populations. Progression-free survival trends favored Jaypirca, especially in ...
Explore 2026 CLL frontline choices, from all-oral acalabrutinib–venetoclax to MRD-guided care, plus pipeline advances and ...
First all-oral, fixed-duration combination regimen approved for previously untreated patients with CLL Approval supported by data from the Phase 3 AMPLIFY trial Regimen offers another option for the ...
ATLANTA, Georgia — A novel investigational therapeutic agent appears to be an effective and safe treatment option for patients with chronic lymphocytic leukemia (CLL). According to 2 new studies ...
In " Beyond Diagnosis: CLL," Cleveland Clinic hematologist/oncologist Allison Winter, MD, and host John Mangels continue ...
Error-corrected sequencing of non–B-cell fractions in CLL12/CLL14 detected CH in ~58% of CLL, with 35% meeting CHIP criteria. Cytotoxic regimens, especially chlorambucil-based therapy, were linked to ...
SAN CARLOS, Calif.--(BUSINESS WIRE)--BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, reaffirms its position as the leader in chronic lymphocytic leukemia (CLL) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results